CVS Health stock weighs higher 2026 outlook after strong quarter

CVS Health raised its full-year 2026 outlook on November 4 after reporting stronger third-quarter results. The company said revenue increased as Health Services and Health Care Benefits expanded, while management kept a cautious view because medical cost trends remain elevated.

CVS Health stock traded at 81.55 euros on Lang & Schwarz at 13:06 CET on Friday, November 13, 2026. A matching Xetra closing-price comparison is not included in this report.

Stronger quarterly performance

CVS Health reported third-quarter revenue of 108.4 billion US dollars, up 5.4 percent from 102.9 billion US dollars a year earlier. Operating income reached 3.6 billion US dollars, compared with an operating loss of 3.2 billion US dollars in the prior-year quarter.

The comparison benefits from a major one-time effect. CVS Health recorded a 5.7 billion US dollar goodwill impairment charge in the third quarter of 2025, while no such charge was recorded in the latest quarter. Adjusted operating income rose 21.2 percent to 4.2 billion US dollars, and adjusted earnings per share increased to 2.09 US dollars from 1.60 US dollars.

CVS Health attributed the improvement in adjusted earnings primarily to higher adjusted operating income in its Health Care Benefits segment. The company also said all operating segments contributed to the increase, although the reported results remain exposed to changing health care utilization and reimbursement conditions.

Insurance segment leads recovery

Health Care Benefits revenue rose 2.4 percent to 36.9 billion US dollars. Adjusted operating income climbed to 912 million US dollars from 314 million US dollars, while the medical benefit ratio improved to 91.3 percent from 92.8 percent. A lower ratio indicates that a smaller share of premium revenue was absorbed by health care costs.

The segment had 26.1 million medical members at September 30, 2026. CVS Health said more than 69 percent of Aetna Medicare Advantage members were enrolled in 2027 plans rated at least four stars by the Centers for Medicare & Medicaid Services.

Health Services revenue increased 9.5 percent to 54.0 billion US dollars, but adjusted operating income rose only 2.7 percent to 2.1 billion US dollars. Pharmacy & Consumer Wellness revenue declined 2.0 percent to 35.5 billion US dollars, although adjusted operating income increased 10.6 percent to 1.6 billion US dollars.

Higher targets, persistent risks

CVS Health raised its minimum 2026 adjusted earnings-per-share outlook to 8.20 US dollars from a previous range of 7.90 to 8.10 US dollars. The minimum GAAP diluted earnings-per-share outlook increased to 6.98 US dollars from a range of 6.84 to 7.04 US dollars. The company also lifted its operating cash flow target to at least 15.5 billion US dollars from at least 11.5 billion US dollars.

Management said the higher targets reflect improved expectations for Health Care Benefits and Pharmacy & Consumer Wellness. At the same time, CVS Health cited continued elevated cost trends and potential macroeconomic headwinds. For investors, the higher outlook improves the earnings framework, but execution in insurance and pharmacy reimbursement remains central to the investment case.

US health care equities remain sensitive to insurer medical costs, prescription pricing and broader market risk. See current S&P 500 market developments for the wider setting.

Further company-specific developments are available in More news and analyses on CVS Health stock.

Source: CVS Health investor relations release.